David L Coffey

US Patent:

7256217, Aug 14, 2007

Filed:

Dec 14, 2001

Appl. No.:

10/250448

Inventors:

David Scott Coffey - Indianapolis IN, US
James Allen Monn - Indianapolis IN, US
Concepcion Pedregal-Tercero - Madrid, ES
Steven Wayne Pedersen - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/16
C07C 233/23

US Classification:

514619, 564193

Abstract:

This invention relates to synthetic excitatory amino acid prodrugs according to formula (I) and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

US Patent:

7381826, Jun 3, 2008

Filed:

Oct 12, 2004

Appl. No.:

10/574712

Inventors:

Alfio Borghese - Rue Granbonpre', BE
David Scott Coffey - Indianapolis IN, US
Pamela Kaye Footman - Indianapolis IN, US
Steven Wayne Pedersen - Indianapolis IN, US
Susan Marie Reutzel-Edens - Zionsville IN, US
Shella Lenyonga Tameze - Indianapolis IN, US
Carsten Timpe - Hamburg, DE
Carsten Weber - Hamburg, DE

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D 401/14
A61K 31/535

US Classification:

546256, 514333

Abstract:

The present invention provides novel crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, compositions thereof, intermediates thereof, methods of using the same, processes for making the same, and processes for making intermediates thereof.

US Patent:

7456221, Nov 25, 2008

Filed:

Jul 5, 2007

Appl. No.:

11/773647

Inventors:

David Scott Coffey - Indianapolis IN, US
James Allen Monn - Indianapolis IN, US
Concepcion Pedregal-Tercero - Madrid, ES
Steven Wayne Pedersen - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/16
C07C 233/23

US Classification:

514619, 564193

Abstract:

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

US Patent:

8168659, May 1, 2012

Filed:

Oct 22, 2007

Appl. No.:

12/441570

Inventors:

David Scott Coffey - Fishers IN, US
Jingdan Hu - Carmel IN, US
Stacy Jo Keding - Zionsville IN, US
John Mehnert Schaus - Zionsville IN, US
David Edward Tupper - Basingstoke, GB

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/4439
C07D 401/12

US Classification:

514343, 5462784

Abstract:

Compounds and pharmaceutical compositions comprising compounds of the Formula.

US Patent:

20040102500, May 27, 2004

Filed:

Sep 11, 2003

Appl. No.:

10/415673

Inventors:

Ivan Cano - Alcobendas, ES
Samuel Dominianni - Indianapolis IN, US
Garret Etgen - Carmel IN, US
Cristina Garcia-Paredes - Alcobendas Madrid, ES
Richard Johnston - Greenfield IN, US
Michael Letourneau - Indianapolis IN, US
Nathan Mantlo - Brownsburg IN, US
Michael Martinelli - Zionsville IN, US
Daniel Mayhugh - Carmel IN, US
Ashraf Saeed - Carmel IN, US
Richard Thompson - Frankfort IN, US
Xiaodong Wang - Carmel IN, US
David Coffey - Indianapolis IN, US
Christopher Schmid - Indianapolis IN, US
Jeffrey Vicenzi - Brownsburg IN, US
Yanping Xu - Fishers IN, US

International Classification:

A61K031/4196
C07D249/12
C 07D 4 3/02

US Classification:

514/384000, 548/263400, 548/263200

Abstract:

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C-Calkyl, aryl-C-alkyl, heteroaryl-C-alkyl, C-Ccycloalkylaryl-C-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C-Calkyl, C-Ccycloalkyl and heteroaryl. X is a C-Calkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH)COOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C-Calkyl, C-Calkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C-Calkyl, C-Calkoxy, C-Ccycloalkyl, arylC-Calkyl and phenyl, or R3 and R4 are combined to form a C-Ccycloalkyl.

US Patent:

20090062358, Mar 5, 2009

Filed:

Jul 26, 2007

Appl. No.:

11/828446

Inventors:

Ivan Collado Cano - Alcobendas, ES
Samuel James Dominianni - Indianapolis IN, US
Cristina Garcia-Paredes - Alcobendas, ES
Richard Duane Johnston - Greenfield IN, US
Michael Edward Letourneau - Indianapolis IN, US
Nathan Bryan Mantlo - Brownsburg IN, US
Michael John Martinelli - Zionsville IN, US
Daniel Ray Mayhugh - Carmel IN, US
Ashraf Saeed - Framingham MA, US
Richard Craig Thompson - Frankfort IN, US
Xiaodong Wang - Carmel IN, US
David Scott Coffey - Indianapolis IN, US
Christopher Randall Schmid - Indianapolis IN, US
Jeffrey Thomas Vicenzi - Brownsburg IN, US
Yanping Xu - Fishers IN, US

International Classification:

A61K 31/4196
C07D 249/12
C07D 405/02

US Classification:

514384, 5482632

Abstract:

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof,R1 is a substituted or unsubstituted group selected from C-Calkyl, aryl-C-alkyl, heteroaryl-C-alkyl, C3-C6 cycloalkylaryl-C-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C-Calkyl, C-Ccycloalkyl and heteroaryl. X is a C-Calkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH)COOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C-Calkyl, C-Calkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C-Calkyl, C-Calkoxy, C-Ccycloalkyl, arylC-Calkyl and phenyl, or R3 and R4 are combined to form a C-Ccycloalkyl.